Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae by Valenzuela Naveda, Myriam et al.
RESEARCH ARTICLE
Antibacterial activity of a DNA topoisomerase I
inhibitor versus fluoroquinolones in
Streptococcus pneumoniae
Myriam V. Valenzuela1, Mirian DomenechID
2, Patricia Mateos-Martı́nez1,
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Abstract
The DNA topoisomerase complement of Streptococcus pneumoniae is constituted by two
type II enzymes (topoisomerase IV and gyrase), and a single type I enzyme (topoisomerase
I). These enzymes maintain the DNA topology, which is essential for replication and tran-
scription. While fluoroquinolones target the type II enzymes, seconeolitsine, a new antimi-
crobial agent, targets topoisomerase I. We compared for the first time the in vitro effect of
inhibition of topoisomerase I by seconeolitsine and of the type II topoisomerases by the fluo-
roquinolones levofloxacin and moxifloxacin. We used three isogenic non-encapsulated
strains and five non-vaccine serotypes isolates belonging to two circulating pneumococcal
clones, ST638 (2 strains) and ST1569V (3 strains). Each group contained strains with diverse
susceptibility to fluoroquinolones. Minimal inhibitory concentrations, killing curves and post-
antibiotic effects were determined. Seconeolitsine demonstrated the fastest and highest
bactericidal activity against planktonic bacteria and biofilms. When fluoroquinolone-suscep-
tible planktonic bacteria were considered, seconeolitsine induced postantibiotic effects
(1.00−1.87 h) similar than levofloxacin (1.00−2.22 h), but longer than moxifloxacin (0.39
−1.71 h). The same effect was observed in sessile bacteria forming biofilms. Seconeolitsine
induced postantibiotic effects (0.84−2.31 h) that were similar to those of levofloxacin (0.99
−3.32 h) but longer than those of moxifloxacin (0.89−1.91 h). The greatest effect was
observed in the viability and adherence of bacteria in the postantibiotic phase. Seconeolit-
sine greatly reduced the thickness of the biofilms formed in comparison with fluoroquino-
lones: 2.91 ± 0.43 μm (seconeolitsine), 7.18 ± 0.58 μm (levofloxacin), 17.08 ± 1.02 μm
(moxifloxacin). When fluoroquinolone-resistant bacteria were considered, postantibiotic
effects induced by levofloxacin and moxifloxacin, but not by seconeolitsine, were shorter,
decreasing up to 5-fold (levofloxacin) or 2-fold (moxifloxacin) in planktonic cells, and up to
1.7 (levofloxacin) or 1.4-fold (moxifloxacin) during biofilm formation. Therefore, topoisomer-
ase I inhibitors could be an alternative for the treatment of pneumococcal diseases, includ-
ing those caused by fluoroquinolone-resistant isolates.
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Introduction
Streptococcus pneumoniae is a main human pathogen. The implementation of the 7-valent and
13-valent conjugate vaccines, which include the serotype-specific polysaccharides more often
associated with resistance to antibiotics, have led to a decline of invasive pneumococcal disease
and penicillin resistance [1]. However, since vaccination only protects against 14–25% of sero-
types, an increase in non-vaccine serotypes has been detected [2–4]. Non-encapsulated iso-
lates, which are the etiological agents of 3–19% of pneumococcal diseases [5,6] and more
prone to form biofilm than encapsulated strains [7], have also emerged.
S. pneumoniae colonizes the human nasopharynx and persists as an asymptomatic com-
mensal [8]. The ability to produce biofilms is essential for this colonization [9] and for its dis-
semination to other body sites [10]. Dissemination leads to the development of sinusitis,
conjunctivitis or acute otitis media and, eventually, invasive diseases, such as bacteremic
pneumonia, meningitis and sepsis [11,12]. Pneumococcal biofilms are not only present in
the nasopharynx, but also in adenoid and mucosal epithelial tissues in children with recur-
rent middle-ear infections and otitis media [13], sinus mucosa of patients with chronic rhi-
nosinusitis [14], and in the lungs of mice infected with S. pneumoniae [15]. The clinical
relevance of biofilms relies also on their capacity to act as a reservoir of antibiotic-resistant
bacteria [16]. Biofilms are 1000-fold more tolerant and/or resistant to antibiotics than plank-
tonic cells [17]. Thus S. pneumoniae biofilms are not effectively cleared during antimicrobial
treatment [18]. In addition, biofilms have an inherent tolerance to host defenses [19]. There-
fore, biofilm antibiotic therapy demands the use of higher doses of antibiotics over pro-
longed periods.
Treatment guidelines for pneumonia recommend respiratory fluoroquinolones (FQs)
[20,21], given their broad spectrum, low resistant rate, excellent penetration into the bronchial
mucosa and a pharmacokinetic profile that facilitates treatment with a single daily dose [22].
FQs target type II DNA topoisomerases: DNA topoisomerase IV (Topo IV: ParC2ParE2) and
DNA gyrase (GyrA2GyrB2). S. pneumoniae has another DNA topoisomerase of type I (topo-
isomerase I, Topo I). These three topoisomerases maintain the DNA topology and solve topo-
logical problems associated with DNA transactions [23].
Resistance to FQs in S. pneumoniae is caused mainly by mutations that change amino acids
of the quinolone resistance–determining regions of the subunits of Topo IV and of GyrA sub-
unit of gyrase [24,25]. Although FQ-resistance in S. pneumoniae is maintained at low preva-
lence (< 3%) in Spain [26,27] and the rest of Europe [28], rates are higher in Canada (7.3%)
[29] and in some locations of Asia (10.5%) [30]. An increase in FQ-resistance in S. pneumoniae
would eventually occur if the FQ use is increased. Finding new antibiotics against S. pneumo-
niae, acting on new targets, is an important clinical need. Topo I has been proposed as a new
antibacterial target [31]. Some alkaloids inhibited in vitro the enzymatic activity of Escherichia
coli Topo I [32]. Our group has reported the inhibition of both Topo I activity and growth of S.
pneumoniae [33] and Mycobacterium tuberculosis [34] by two new boldine-derived alkaloids,
seconeolitsine (SCN) and N-methyl-seconeolitsine, without affecting human cell viability. The
specific inhibition of Topo I by SCN in vivo is supported by the attenuation of growth inhibi-
tion under conditions of Topo I overproduction in S. pneumoniae [33], and by an increased
susceptibility in a M. tuberculosis strain that has lower levels of Topo I [34]. In addition, SCN
causes hyper-negative supercoiling in replicating plasmids in both species [33−35], consistent
with the inhibition of Topo I, the main DNA-relaxing enzyme in these bacteria. This increase
in supercoiling in S. pneumoniae triggers a coordinated global transcriptional response [35].
Therefore, Topo I could be considered a suitable new drug target, and boldine-derived alka-
loids are attractive lead-compounds for further antibiotic development.
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The aim of this study was to analyze the main DNA topoisomerases of S. pneumoniae as
antibiotic targets by comparing the effects of inhibiting these enzymes in planktonic bacteria
and biofilms. The antibacterial activity of SCN (Topo I inhibitor) was compared with that of
two respiratory FQs, levofloxacin (LVX) and moxifloxacin (MXF), which inhibit the type II
DNA topoisomerases. Minimal inhibitory concentrations (MICs), killing-curves and post anti-
biotic effects (PAEs) were tested and compared for the three compounds.
Material and methods
Bacterial strains
Eight S. pneumoniae strains were used (Table 1): 3 isogenic laboratory strains (R6, T1 and T2)
that have been previously characterized [36], and two groups of clinical isolates belonging to
two circulating pneumococcal clones (ST638 and ST1569V). Isolates belonging to the ST638 and
ST1569V clones were selected from our previous study [26]. Each group included strains with
different susceptibility to ciprofloxacin (CIP) due to mutations in parC or both parC and gyrA.
Susceptibility tests
MICs were determined by the microdilution method, based on the Clinical and Laboratory
Standards Institute procedure [37]. Serial 2-fold dilutions of the antibiotics (between 64 and
0.03 μg/ml), were dispensed into 96-well polystyrene microtiter plates with bacteria cultures at
a concentration of 105 colony-forming units (CFU)/ml (200 μl final volume). Media used,
named AGCH, was a casein hydrolysate-based medium with 0.3% sucrose and 0.2% yeast
extract [38]. Plates were incubated at 37˚C for 24 h in the presence of 5% CO2. The MIC was
defined as the lowest concentration of drug without visible growth.
Killing assays
The kinetics of killing of planktonic bacteria was studied in AGCH (a suitable medium for
planktonic growth). Bacteria were treated with the drugs for 8 h by exposing 200 μl of about
Table 1. Characteristics of S. pneumoniae strains.
Groupa Strainb Description Residue change MIC (μg/ml)c Microbiological susceptibility
categorizationd
CIP LVX MXF SCN CIP LVX MXF
Laboratory strains R6 Avirulent, uncapsulated None 0.5 1 0.06 8 S S S
T1 R6 derivative, ParC S79F 4 1 0.06 4 LL-R S S
T2 T1 derivative ParC S79F 32 16 2 4 HL-R HL-R HL-R
GyrA S81F
ST638 clone 2390 Blood isolate ParC S79F 8 2 0.25 4 LL-R S S
3498 Blood isolate ParC S79F 32 16 4 4 HL-R HL-R HL-R
GyrA S81F
ST1569V clone 3360 Eye isolate None 1 0.5 0.06 4 S S S
2194 Sputum isolate ParC S79Y 4 1 0.12 4 LL-R S S
1920 Bronchoalveolar isolate ParC S79F 64 16 2 4 HL-R HL-R HL-R
GyrA S81F
a Clone is named as sequencing type (ST) with the serotype in superscript.
b Strains R6, T1 and T2 have been previously characterized [36]. The rest of isolates were selected from our previous studies [26].
c MICs were determined by the microdilution method. The results are the average of three independent replicates.
d S, susceptible. LL-R, low-level resistant: CIP MIC� 4 μg/ml, LVX MIC > 2 μg/ml; MXF MIC� 1 μg/ml. HL-R, high-level resistance: CIP MIC�16 μg/ml, LVX
MIC� 16 μg/ml, MXF MIC� 4 μg/ml.
https://doi.org/10.1371/journal.pone.0241780.t001
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104 CFU/ml of R6 strain at sub-inhibitory (0, 1/8 ×, 1/4 ×, 1/2 × MIC) or inhibitory concentra-
tions (1 ×, 2.5 ×, 5 ×, 10 × MIC) in 96-well polystyrene microtiter plates. Plates were incubated
at 37˚C with 5% CO2. Viable count was determined by plating 50 μl on Mueller-Hinton Blood
Agar plates (Becton Dickinson). Biofilm formation was determined by the ability of cells to
adhere to the walls and base of 96-well (flat-bottom) polystyrene microtiter plates (Costar
3595; Corning Incorporated), using a modification of a previously reported protocol [39]. R6
was grown to an OD595 = 0.5 in CpH8 medium (a suitable medium for the formation of bio-
films) containing 33 mM potassium phosphate buffer at pH 8.0 [40]. Then, bacteria were
diluted 1/100 and dispensed in the microtiter plates (200 μl per well). Plates were incubated at
34˚C for 6 h to develop the biofilm. Then, cultures were rinsed with fresh media and concen-
trations equivalent to 5 × MIC of LVX, MXF or SCN were added and plates were incubated
for 24 h at 34˚C. Biofilm formation was analyzed by staining with crystal violet.
Post antibiotic effects (PAE) in planktonic bacteria
PAE in planktonic bacteria was calculated by measuring bacteria re-growth after antibiotic treat-
ment using the viable plate count method [41]. 108 CFU/ml of bacteria in AGCH were treated for
1 h with different drug concentrations in 24-well (flat bottom) polystyrene microtiter dishes. The
treatment was finished by a 1/1000 dilution with fresh media, and cultures were incubated for 6 h.
Viable bacteria (CFUs) were counted every 2 h by plating 50 μl of culture on Mueller-Hinton
blood agar plates. PAE was quantified with the formula PAE = T- C. It measures the time required
for the viable bacteria counts to increase by 1 log10 above the counts observed immediately after
washing in exposed cultures (T) regarding antibiotic unexposed cultures (C). PAE� 0.5 h was
considered significant [42]. Viability of R6 in PAE-phase was observed with a fluorescence
microscopy OLYMPUS BXG1 every 2 h after the end of the treatment. A LIVE/DEAD BacLight
bacterial viability kit L-7012 (Invitrogen-Molecular Probes) was used to monitor the viability of
bacterial populations as a function of the membrane integrity of the bacteria: cells with a compro-
mised membrane are considered to be damaged (stain yellow) or dead (stain red); whereas cells
with an intact membrane will stain green [43]. BacLight-stained cells were observed under fluores-
cence microscopy (Olympus BXG1). At least 100 cells were analyzed for viability.
PAE in biofilm
R6 and T2 strains were grown in CpH8 medium to OD595 = 0.5, diluted 1/100 and dispensed in
96-well flat-bottom polystyrene microtiter dishes. Plates were incubated at 34˚C to get 106 CFU/
ml adhered to the walls base. Then, attached bacteria were treated with drugs during 1 h at 34˚C.
Drug treatment was finished by rinsing cultures three times with CpH8 and plates were incubated
for 6 h. PAE was quantified by viable count method. At each time point, wells were washed three
times with CpH8 and filled with phosphate-buffered saline to remove planktonic bacteria. The
surfaces of the wells were vigorously scraped and the number of viable cells was estimated by plat-
ing 50 μl of culture on Mueller-Hinton Blood Agar. Bacteria in the biofilm was estimated by stain-
ing with crystal violet (50 μl of a 1% solution was added to each well), measuring A595 using a
microplate absorbance reader 2020 (Anthos Labtec Instruments GmbH). Plates were then incu-
bated at room temperature for 15 min, rinsed 3 times with 200 μl of water, and air dried. Stained
biofilm was quantified by solubilizing it with 95% ethanol (200 μl/well) and determination of
A595. Structure of biofilms was also observed by confocal laser scanning microscopy. Bacteria
were grown on glass-bottom dishes (WillCo-dish; WillCo Wells B. V., The Netherlands) in 2 ml
of CpH8 medium for 1.5 h at 34˚C to get a biofilm with 106 CFU/ml of viable bacteria. Culture
medium containing planktonic bacteria was removed, and the biofilms were incubated in CpH8
with the drug for 1 h at 34˚C. Then, antibiotic was rinsed 3 times with CpH8. Controls were run
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with the same amount of CpH8 without antibiotics. Biofilms were also stained with the bacterial
viability BacLight kit (InvitrogenTM, Thermo Fisher Scientific), showing viable (green fluores-
cence) and non-viable (red fluorescence) bacteria. After staining, they were rinsed with 0.5 ml of
phosphate-buffered saline. Observations were made using a Leica TCS-SP2-AOBS (Acousto Opti-
cal Beam Splitter)-UV (Ultraviolet) or Leica TCS-SP5-AOBS confocal microscope (Mannheim,
Germany) with objective HPX PL APO CS 63X/1.4 oil immersion and zoom 2. Laser line at
488nm for excitation of SYTO9, and Alexa fluor-488 were provided by an Argon laser and laser
line 561nm for excitation of Propidium iodide (PI) a DiodeP Solid State laser. Detection ranges
were set to eliminate crosstalk between fluorophores. The image resolution was 8 bits and format
512 × 512 pixels. Laser intensity and gain were kept the same for all images. Images were analyzed
using LCS software from LEICA. Maximum intensity projections were obtained in the x–y (indi-
vidual scans at 0.5–1 μm intervals) and x–z (images at 5–6 μm intervals) planes.
Statistical analysis
Data for the assays include the mean ± standard error of at least two independent experiments.
For multiples comparisons, one-way analyses of variance (ANOVA) with 95% significance
level were performed. The Statgraphics Statgraphics Centurion XVI statistical packge was used
for all analyses. Differences were considered statistically significant when P<0.05.
Results
SCN shows higher and faster bactericidal activity than FQs against S.
pneumoniae R6
MICs of three FQs and SCN against eight bacterial strains were determined (Table 1). The
strains tested include three isogenic non-encapsulated strains (R6, T1 and T2), and five clinical
isolates belonging to two circulating pneumococcal clones, ST638 (2 strains) and ST1569V (3
strains). Within each group, there were strains with both low level of resistance (LL-R) to CIP
(carrying mutations in parC), and strains with high-resistance (HL-R) to CIP (carrying muta-
tions in both parC and gyrA). The breakpoints of the Clinical and Laboratory Standards Insti-
tute [30] were considered for LVX and MXF. Breakpoints for CIP were taken from our
previous studies [26,27]. Strains were considered susceptible to SCN if their MICs were similar
to strain R6 (8 μg/ml = 25 μM), based on a previous study [33]. The five strains LL-R to CIP
were susceptible to LVX and MXF. The three strains HL-R to CIP were also highly resistant of
LVX and MXF. However, all strains were susceptible to SCN.
Killing-curves of planktonic bacteria (Fig 1A) demonstrated similar dead kinetics at supra-
MIC concentrations with any of the three drugs. Decrease in CFUs was proportional to the
concentration of drug used and to the duration of the treatment. MXF showed greater bacteri-
cidal activity than LVX, decreasing CFU to less than 2 Log10 at concentrations� 2.5 × MIC
after 6 h, while for LVX this decrease was only observed at higher concentrations (10 × MIC)
after longer treatments (8 h). SCN showed the highest bactericidal activity, reducing viability
of planktonic cells to less than 2 Log10 after 4 or 6 h of treatment with 10 × MIC or 5 × MIC,
respectively. SCN and MXF, but not LVX, reduced also biomass of biofilm at 5 × MIC after 24
h of treatment (Fig 1B), being SCN the most effective drug.
PAEs were longer in planktonic bacteria when the target of the treatment
was Topo I, independently of the susceptibility to FQs
To analyze the influence of FQ-susceptibility in PAE induced by FQs or SCN, we used strains
with similar genotypes but different amino acid changes associated to FQ-resistance. FQs
PLOS ONE Inhibition of DNA topoisomerases of S. pneumoniae
PLOS ONE | https://doi.org/10.1371/journal.pone.0241780 November 3, 2020 5 / 16
Fig 1. Bactericidal activity of drugs against strain S. pneumoniae R6. (A) Planktonic bacteria killing-curves in the
absence or presence of the indicated drugs, which chemical structures are showed on the right. DL, detection limit (B)
Inhibition of 6h-biofilm treated with 5 × MIC for 24 h, quantified by crystal violet staining. The results are the
mean ± SD of two (A) and three (B) independent experiments. �, P< 0.05 versus untreated.
https://doi.org/10.1371/journal.pone.0241780.g001
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induced a significant PAE at 10 × MIC in all strains (Table 2). However, at 2.5 × MIC no sig-
nificant PAE either in the non-encapsulated Cip-resistant strains or in the HL-Cip-resistant R
isolate of the ST638 clone was induced. PAE induced by MXF were similar or longer than that
induced by LVX. PAE induced by either of the two FQs was shorter in resistant strains than in
susceptible strains. In contrast, SCN induced significant PAE in all strains at every concentra-
tion used and there were no differences between susceptible and FQ-resistant strains. In addi-
tion, SCN induced PAEs longer than that induced by LVX and/or MXF (Table 2).
The viability of planktonic bacteria in PAE phase was estimated for the R6 strain by fluores-
cence microscopy (Fig 2). Treatments of 1 h with 2.5−10 × MIC decreased living bacteria by
up to 75–57%, 77–62% and 65–52%, for LVX, MXF and SCN, respectively, whereas in control
cultures these values were of up to 80% (0 h in Fig 2). Four hours after finishing the treatment
(4 h in Fig 2), an increase in live bacteria close to the control values was observed for the FQs,
but not for SCN (74–68%). Therefore, SCN treatment was the most effective in reducing bacte-
ria viability, not only when the antibiotic was present but also after removing it.
SCN was more effective than FQs in reducing PAE, adherence and
thickness of biofilms
PAE induced after 1 h of treatment with 1−5 × MIC of LVX, MXF or SCN in R6 sessile bacte-
ria forming biofilms was determined. The three drugs induced a significant PAE in planktonic
cells (Table 3). They also induced PAE in sessile bacteria forming biofilms, with the exception
of MXF at 1 × MIC in the resistant strain T2. Although T2 and R6 demonstrated similar capac-
ity to form biofilm (S1 Fig), PAE induced by FQs, but not by SCN, was shorter in the resistant
T2 strain than in the susceptible R6 strain.
PAE induced in sessile bacteria after treatment delayed their growth (viable counting in Fig
3A), and reduced biofilm formation (Fig 3A). The biofilm was thinner, the higher the concen-
tration used in the treatment. PAE and biofilm reduction were greater after treatments with
SCN or LVX than with MXF. Thus, 6 h after the end of the treatment with 1, 2.5, or 5 × MIC,
A595 of biofilm remained 0, 2.7 or 10-fold lower than the untreated biofilm for LVX while it
Table 2. PAE in planktonic S. pneumoniae strains after 1 h exposure to drugs, measured by viable count method.
Group Strain PAE (h ± SD)a
LVX (× MIC) MXF(× MIC) SCN(× MIC)
2.5 10 2.5 10 2.5 10
Laboratory strains R6 1.02 ± 0.12 1.67 ± 0.06 0.39 ± 0.12 1.33 ± 0.29 1.00 ± 0.05 1.87 ± 0.12
T1 0.40 ± 0.05 � 0.70 ± 0.06 � 0.00 ± 0.00 0.66 ± 0.05 � 1.03 ± 0.06♦ 1.95 ± 0.20 ♦
T2 0.28 ± 0.05 �• 0.56 ± 0.11 � 0.48 ± 0.07 0.70 ± 0.11 � 0.89 ± 0.21♦ 1.98 ± 0.13 ♦
ST638 clone 2390 1.41 ± 0.21 1.68 ± 0.29 1.43 ± 0.35 2.56 ± 0.13 1.68 ± 0.29 2.22 ± 0.19 ♦
3498 0.57 ± 0.10 • 1.18 ± 0.23 1.10 ± 0.26 1.99 ± 0.16 • 1.77 ± 0.10 ♦ 2.22 ± 0.07 ♦
ST1569V clone 3360 1.22 ± 0.17 2.06 ± 0.35 0.90 ± 0.21 1.71 ± 0.31 1.52 ± 0.10 1.76 ± 0.17
2194 0.77 ± 0.10 � 1.09 ± 0.02� 0.74 ± 0.04 � 1.45 ± 0.13 1.60 ± 0.31 ♦ 1.88 ± 0.32 ♦
1920 0.22 ± 0.05 �• 0.97 ± 0.07� 0.49 ± 0.12 � 1.00 ± 0.15 �• 1.62 ± 0.20 ♦ 1.72 ± 0.25 ♦
a PAE values considered significant (� 0.5 h) are indicated in boldface. Results are the average ± SD of three independent replicates. Significant differences in PAE
values (P< 0.05):
♦longer with SCN than with LVX at similar concentration in the same strain
longer with SCN than withMXF at similar concentration in the same strain
�shorter in the CipR strain than in the CipS strain of similar genotype
• shorter in the HL-R strain than in the LL-CipR strain of similar genotype.
https://doi.org/10.1371/journal.pone.0241780.t002
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Fig 2. Viability of planktonic R6 in PAE-phase. Cultures containing 108 CFU/ml were exposed for 1 h to the indicated drug concentrations,
diluted 1000-fold in drug-free media and incubated during 6 h. (A) Quantification of alive (black bars), damaged (hatched bars), or dead (white
bars) bacteria in PAE-phase stained with the BacLight kit and counting by fluorescence microscopy BXG1 (100 bacteria for each condition). (B)
Growth kinetics of bacteria in PAE-phase. The results are the mean ± SD of two or three independent experiments.
https://doi.org/10.1371/journal.pone.0241780.g002
Table 3. PAE in sessile S. pneumoniae strains forming biofilms after 1 h exposure to drug, measured by viable count method.
Strain PAE (h ± SD)a
LVX (× MIC) MXF (× MIC) SCN (× MIC)
1 2.5 5 1 2.5 5 1 2.5 5
R6 0.99 ± 0.16 2.23 ± 0.10 3.32 ± 0.03 0.89 ± 0.18 1.20 ± 0.21 1.91 ± 0.24 0.84 ± 0.09 1.26 ± 0.08 2.31 ± 0.36
T2 1.21 ± 0.18 1.57 ± 0.27� 1.89 ± 0.37� 0.25 ± 0.17� 0.76 ± 0.13� 1.34 ± 0.15� 0.76 ± 0.12 1.53 ± 0.19 2.47 ± 0.07 ♦
a PAE values, considered significant (� 0.5 h) are indicated in boldface. Results are the average ± SD of three independent replicates. Significant differences in PAE
values (P< 0.05)
♦ longer with SCN than with LVX at similar concentration in the same strain
longer with SCN than with MXF at similar concentration in the same strain
� shorter in the HL-R strain T2 than in the S strain R6.
https://doi.org/10.1371/journal.pone.0241780.t003
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was 1.5, 2.5, or 5-fold lower for SCN (Fig 3A). However, only after treatment with� 5 × MIC
of MXF a reduction of the biofilm formation was observed and only at 4 h.
The evolution and architecture of biofilms formed by strain R6 in the PAE-phase were stud-
ied by confocal laser scanning microscope after drug treatment with 5 × MIC. Viability of bac-
teria in the biofilm was monitored using the BacLight LIVE/DEAD bacterial viability kit (Fig
3B). Treatment of 1 h with either SCN or LVX, but not with MXF, killed most bacteria (0 h in
Fig 3B), being the thickness of biofilms of 10.09 ± 0.79 μm (control), 7.18 ± 0.58 μm (LVX),
17.08 ± 1.02 μm (MXF) and 2.91 ± 0.43 μm (SCN). Therefore, the thickness of biofilms was
lower under treatment with LVX (about 1.4-fold) or SCN (about 3.5-fold) than in the
untreated control. Recovery of the biofilm was observed after 4 h of finishing the treatment
with SCN or LVX (4h in Fig 3B). S. pneumoniae biofilm formation requires the presence of
extracellular DNA as a component of the extracellular matrix, which is needed to establish and
maintain pneumococcal biofilms [7]. After treatment of 1h with DNAaseI, the biofilm was
practically eliminated. However, after 2 and 4h of finishing DNAaseI treatment, both biofilm
and viable bacteria recovered (Fig 3B).
Discussion
The environment influences different bacterial factors (virulence, motility, biofilm formation,
antimicrobial susceptibility) by modulating the supercoiling of bacterial DNA [44]. The level
of supercoiling in S. pneumoniae is regulated by the activity of their DNA topoisomerases, i.e.,
gyrase, Topo IV and Topo I [23]. Mutant gyrase and Topo IV enzymes, present in FQ-resistant
isolates, have lower activities than wild-type enzymes, influencing the supercoiling level [45].
Therefore, to study the activity of the Topo I inhibitor SCN, it was necessary to consider both
wild-type strains and isogenic derivatives carrying gyrase and Topo IV mutations (R6, T1 and
T2). These strains are non-encapsulated. Clinical non-encapsulated pneumococci represent an
emerging problem in pneumococcal infections. In addition, five clinical strains were also
included. They belong to the two clones more closely related with FQ resistance in Spain in
2009, as a consequence of the introduction of PCV7, ST1569V and ST638 ☯26]. All strains
studied were susceptible to SCN, regardless of their susceptibility to FQs.
Our data shows a higher bactericidal activity for MXF than for LVX in planktonic bacteria
and in inhibition of 6h-biofilm after 24 h treatment. This is in accordance with previous stud-
ies showing greater in vitro activity [46], faster rates of killing [47], and more in vivo efficacy
[48] of MXF compared to LVX or other fluoroquinolones [49,50] against planktonic S. pneu-
moniae. Likewise, MXF has been showed to be more effective than LVX in disrupting S. pneu-
moniae biofilms 6h-biofilm at concentrations achieved in the bronchial mucosa [51]. Another
study reports a lower activity of LVX against pneumococcal biofilms than against planktonic
cells [52], which supports our results. Other authors also reported that MXF reduced more
than LVX the viability of 2 days-biofilm of R6 [53]. In any case, the compound that showed the
highest and fastest bactericidal activity against planktonic and biofilms in our study was SNC.
The bactericidal activity of other alkaloids against streptococci has been identified very
recently, such as berberine against Streptococcus agalactiae [54] or alkaloids from seeds of the
Sterculia lychnophora tree against Streptococcus mutans [55].
Fig 3. Biofilm formation by R6 in PAE-phase. About 106 CFU/ml attached bacteria were treated for 1 h with the indicated drugs.
Treatment was finished by washing and bacteria were incubated at 34˚C for 6 h. (A) Growth kinetics of sessile bacteria forming the
biofilm (viable counting) and quantification of bacteria in the biofilm (staining with crystal violet). The results are the mean ± SD of
four independent experiments. �, P< 0.05 versus untreated. Bt, before treatment. (B) Confocal structure of the biofilm after treatment
at 5 × MIC (confocal microscopy) and a control treated with DNAseI at 50 μg/ml, which has been showed to disrupt biofilms [44]
Scale bars 25 μm.
https://doi.org/10.1371/journal.pone.0241780.g003
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This study also established that LVX, MXF and SCN were able to induce PAE in planktonic
bacteria and biofilms. PAE is an important pharmacodynamic parameter with a great clinical
significance. For many compounds it has been demonstrated that prolonged in vitro PAEs
may also suppress bacterial growth in vivo during periods of low drug concentration [56]. PAE
needs to be considered in antibacterial dosing regimens, so that the greater the PAE induced
by an antibiotic, the less frequently it should be administered. This will reduce toxicity, devel-
opment of resistance, and treatment costs [57]. The clinical relevance of this effect will be even
greater in biofilms, which need longer treatments. PAE is a well-established parameter for dif-
ferent kind of antibiotics against several bacteria on planktonic state. Some studies, which sup-
port our results, have reported that PAE induced by LVX [58] or MXF [59] in planktonic
cultures of S. pneumoniae. We have recently studied the molecular mechanisms involved in
this process and found that the production of reactive oxygen species, which is a consequence
of transcriptional alterations induced by the drugs, is a major PAE contributor [60]. However,
PAE has never been studied in biofilms. As far as we know, this is the first study that analyzes
the biofilm formation capacity of S. pneumonaie surviving treatment. Interestingly, we
observed that MXF induced PAE similar or longer than LVX in planktonic bacteria (exponen-
tial phase), but shorter in sessile bacteria forming biofilms (stationary phase), suggesting a rela-
tion between PAE and growth phase. These results agree with previous studies showing that
the bactericidal activity of MXF was greater than that of LVX in the exponential growth phase,
but the opposite was true in the stationary phase [61]. In the present study, MXF reduced bio-
film formation more efficiently than LVX in treatments of 24 h, i.e., long enough not to be
influenced by the growth phase. However, short treatments, used to induce PAE, were strongly
influenced by the stationary phase of the biofilm, demonstrating that LVX has a higher bacteri-
cidal activity than MXF, causes a higher reduction in the viability of sessile pneumococci and
induces longer PAE. Once again, SCN was more effective than FQs, inducing longer PAE in
planktonic bacteria. SCN also induced longer PAE than MXF in biofilm. Moreover, SCN was
the compound causing the highest reduction in the viability and adhesion of sessile bacteria,
decreasing biofilm thickness and the size of monolayers. Recent studies in Pseudomonas aeru-
ginosa support the relationship established in our study between TopoI and the formation of
biofilms [62]. It has also been described the anti-biofilm effect of other alkaloid, based on the
inhibition of effective adhesion and growth of bacteria forming the biofilm [63]. If adequate
levels of SCN can be achieved in vivo, the low adherence after alkaloid treatment could imply a
clinical advantage, since SCN could prevent or obstruct the chronicity of infections associated
with the formation of biofilms [64].
In this study, we found an additional advantage of SCN compared to LVX and MXF. Both
FQs, but not SCN, showed a significant decrease in its inhibitory activity against resistant
strains and induced shorter PAE in them than in susceptible strains. As higher was the resis-
tance to FQs, the shorter was the PAE induced by both FQs, decreasing up to 5-fold (LVX) or
2-fold (MXF) in planktonic cells, and up to 1.7 (LVX) or 1.4−fold (MXF) during biofilm for-
mation. These results confirmed similar observations in other gram-positive cocci. PAE
induced by LVX and gatifloxacin in FQ-sensitive Staphylococcus aureus strains were shorter
than those observed in resistant strains [65]. For vancomycin-resistant strains of Enterococcus
faecium, the PAEs were considerably shorter than those for vancomycin-susceptible strains
[66].
Summarizing, Topo I is an appropriate antimicrobial target in S. pneumoniae, especially in
strains resistant to inhibitors of other topoisomerases (FQs). TopoI inhibitors such as SCN
showed faster and higher bactericidal activity than FQs regardless of growth phase; induced
longer PAEs in planktonic bacteria, reduced more than FQs the thickness of mature biofilm
and interfered with biofilm formation. In addition, TopoI inhibitor activity did not decrease in
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FQ-resistant strains. All these results support Topo I inhibitors as new therapeutic candidates
for the treatment of pneumococcal diseases and for the prevention of the chronicity of the
pneumococcal disease.
Supporting information
S1 Fig. Biofilm formation capacity of R6 and T2. Strains were grown in CpH8 to OD595 =
0.5, diluted 1/100 and dispensed in 96-well flat-bottom polystyrene microtiter dishes. Plates
were incubated at 34˚C to get 106 CFU/ml of cultivable bacteria adhered to the walls base.
Then, attached bacteria were rinsed three times with CpH8 and incubated for 6 h to analyze
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